• Explore /
  • Poster
  • / Efficacy and safety of the anti–PD-L1 monoclonal antibody socazolimab for recurrent or metastatic cervical cancer: Results from the phase I dose-escalation and expansion study.

Efficacy and safety of the anti–PD-L1 monoclonal antibody socazolimab for recurrent or metastatic cervical cancer: Results from the phase I dose-escalation and expansion study.

Abstract Poster

Authors

null

Jusheng An

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

Jusheng An , Li Guiling , Jie Tang , Benjamin Xiaoyi Li , Hui Hua Xiong , Hui Qiu , Lin Luo , Li Wang , Danbo Wang , Qi Zhou , Qin Xu , Hong Lin Song , Yun Yan Zhang , Hong Ping Zhang , Rachel Ng , Zewei Zhao , Xiang Rong Dai , Yu Jie Li , Yuanjue Sun , Lingying Wu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Cervical Cancer

Clinical Trial Registration Number

NCT03676959

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5526)

DOI

10.1200/JCO.2022.40.16_suppl.5526

Abstract #

5526

Poster Bd #

405

Abstract Disclosures

Similar Posters

First Author: Igor Tsaur

First Author: Jianqing Zhu

First Author: Jihong Liu

First Author: Peter Schmid